We are Virvio | Minibinders | Innovative | Medicines

Virvio designs innovative medicines that improve people's lives. Our computational drug discovery platform rapidly optimizes synthetic biotherapies that are easy to manufacture, shelf stable and outperform known antibodies.

Our Minibinders Get In Touch
Come learn about Virvio

Minibinder Medicines

Virvio is changing how ordinary people get treated for common diseases. Our minibinder medicines mimic proven monoclonal antibodies with safer, more effective biologic alternatives. These medicines represent a new era of accessible treatments for indications like asthma, flu and neuropathic pain.

Old Antibody Interaction

Traditional monoclonal antibodies have proven effects but also many well-known limitations. They are relatively clumsy by today’s biotechnology standards and can have serious toxicity issues compared to alternative biotherapeutics.

New Minibinder Interaction

Virvio minibinders confer the same advantages as traditional biologics. Unlike other biologics, our design algorithms are also able to tailor scaffold characteristics and structures that are unattainable with other methods.

The Virvio difference - in 60 Seconds

We are proud of these

Amazing Numbers

> 700
Scaffolds made
~ 1 nM
Affinity to target
18
Months per lead
$3M
Cost per lead

Want more info on our anti-flu minibinder?

We truly appreciate these

Great Partners

Here is some important

Virvio News

Event – 2017 PEGS Boston

PEGS Boston 2017 (Cambridge Healthtech Institute) – Virvio will present “Computational Design of de novo Anti-Influenza Minibinder Proteins” during the Engineering Antibodies session in the Engineering Stream. (http://www.pegsummit.com/Engineering-Antibodies/)

Event – 2016 BioPharm America

EBD Group – Global drug development executives converge on Boston for BioPharm America™ 2016 (http://www.ebdgroup.com/corp/global-drug-development-executives-converge-on-boston-for-biopharm-america-2016/)